Improved clinical outcomes with multi-modality therapy for sinonasal undifferentiated carcinoma of the head and neck

Am J Otolaryngol. 2013 Nov-Dec;34(6):658-63. doi: 10.1016/j.amjoto.2013.06.005. Epub 2013 Aug 29.

Abstract

Objective: To examine outcomes among patients treated for sinonasal undifferentiated carcinoma (SNUC) of the head and neck.

Study design: Retrospective review.

Methods: The records of 16 consecutive patients with newly diagnosed, non-metastatic SNUC were analyzed. Initial treatment consisted of: surgery alone (6 patients), surgery with post-operative chemoradiotherapy (4 patients), and primary radiation therapy with concurrent chemotherapy (6 patients).

Results: The median survival for patients treated by surgery followed by postoperative chemoradiotherapy was 30 months compared to 7 months and 9 months for patients treated by surgery alone and upfront chemoradiotherapy, respectively (p=0.20). The 2-year locoregional control was 18% for patients treated with upfront chemoradiotherapy, 37% for patients treated with surgery alone, and 78% for patients treated with surgery plus chemoradiotherapy (p=0.49).

Conclusion: While the potential role of selection bias must be considered, multi-modality therapy using surgery and post-operative chemoradiotherapy yielded the most favorable outcomes for SNUC and should be recommended whenever feasible.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Carcinoma / mortality*
  • Carcinoma / pathology
  • Carcinoma / therapy*
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Male
  • Maxillary Sinus / surgery
  • Maxillary Sinus Neoplasms / mortality*
  • Maxillary Sinus Neoplasms / pathology
  • Maxillary Sinus Neoplasms / therapy*
  • Middle Aged
  • Neck Dissection
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local
  • Paclitaxel / administration & dosage
  • Retrospective Studies

Substances

  • Etoposide
  • Carboplatin
  • Paclitaxel
  • Cisplatin

Supplementary concepts

  • Sinonasal undifferentiated carcinoma